Uterine artery embolization is a minimally invasive treatment for symptomatic uterine fibroids, but intra-procedural assessment of embolization adequacy currently relies on subjective angiographic criteria. This study evaluates a proprietary angiographic analysis software (AQ-VERO) that extracts quantitative time-to-density perfusion metrics in real time. The study aims to (1) validate the accuracy and reproducibility of AQ-VERO during uterine artery mebolization, and (2) develop an AI-based decision support system using AQ-VERO-derived metrics to improve objective intra-procedural assessment of treatment endpoints.
Female patients ≥18 years
Symptomatic uterine fibroids (e.g., bleeding, bulk symptoms, pain)
Underwent UAE as definitive therapy
Availability of baseline clinical/imaging data (for retrospective arm) or ability to provide informed consent (for prospective arm)
Lack of clinical follow-up
Poor quality or incomplete angiographic images.
Emanuele Barabino
Lead sponsor
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Sponsor institution